{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:34:38Z","timestamp":1794339278208,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00705-025-06382-7","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:19:08Z","timestamp":1755274748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of recent pre-booster studies on hepatitis B vaccine effectiveness across WHO regions with HBV prevalence above 1% in the general population up to 60 years of age: a systematic review"],"prefix":"10.1007","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7277-1103","authenticated-orcid":false,"given":"Tahereh","family":"Zadeh Mehrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Eshrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ebrahimi Shahmabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"6382_CR1","unstructured":"World Health Organization (2024) Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva"},{"issue":"3","key":"6382_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/vaccines12030288","volume":"12","author":"SA Al-Busafi","year":"2024","unstructured":"Al-Busafi SA, Alwassief A (2024) Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030. Vaccines 12(3):288. https:\/\/doi.org\/10.3390\/vaccines12030288","journal-title":"Vaccines"},{"issue":"2","key":"6382_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.livres.2024.05.004","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed W, El-Kassas M (2024) Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do. Liver Res 8(2):83\u201390. https:\/\/doi.org\/10.1016\/j.livres.2024.05.004","journal-title":"Liver Res"},{"key":"6382_CR4","doi-asserted-by":"publisher","unstructured":"Wahid A, Ali A, Roobi A et al (2024) Status of vaccination against Hepatitis B Virus. In book: Complementary and alternatives Medicines, Publisher: Unique Scientific Publishers, pp 288\u2013294. https:\/\/doi.org\/10.47278\/book.CAM\/2024.263","DOI":"10.47278\/book.CAM\/2024.263"},{"issue":"6","key":"6382_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/1060028020962050","volume":"55","author":"CR Champion","year":"2021","unstructured":"Champion CR (2021) Heplisav-B: a hepatitis B vaccine with a novel adjuvant. Ann Pharmacother 55(6):783\u2013791. https:\/\/doi.org\/10.1177\/1060028020962050","journal-title":"Ann Pharmacother"},{"issue":"12","key":"6382_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.5301\/ijao.5000458","volume":"38","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi F, Martin P, Messa P (2015) Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs 38(12):625\u2013631. https:\/\/doi.org\/10.5301\/ijao.5000458","journal-title":"Int J Artif Organs"},{"issue":"1","key":"6382_CR7","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/14760584.2023.2274482","volume":"22","author":"T Vesikari","year":"2023","unstructured":"Vesikari T, Langley JM, Popovic V, Diaz-Mitoma F (2023) PreHevbrio: the first approved 3-antigen hepatitis B vaccine. Expert Rev Vaccines 22(1):1041\u20131054. https:\/\/doi.org\/10.1080\/14760584.2023.2274482","journal-title":"Expert Rev Vaccines"},{"issue":"32","key":"6382_CR8","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1016\/s0264-410x(01)00240-7","volume":"19","author":"RW Joines","year":"2001","unstructured":"Joines RW, Blatter M, Abraham B et al (2001) A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix\u00ae) with corresponding monovalent vaccines (Havrix\u00ae and Engerix-B\u00ae) in adults. Vaccine 19(32):4710\u20134719. https:\/\/doi.org\/10.1016\/s0264-410x(01)00240-7","journal-title":"Vaccine"},{"issue":"1","key":"6382_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40272-016-0208-y","volume":"19","author":"YY Syed","year":"2017","unstructured":"Syed YY (2017) DTaP5-HB-IPV-Hib vaccine (Vaxelis\u00ae): a review of its use in primary and booster vaccination. Paediatr Drugs 19(1):69\u201380. https:\/\/doi.org\/10.1007\/s40272-016-0208-y","journal-title":"Paediatr Drugs"},{"issue":"12","key":"6382_CR10","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3390\/vaccines11121862","volume":"11","author":"F Mahmood","year":"2023","unstructured":"Mahmood F, Xu R, Awan MUN et al (2023) HBV vaccines: advances and development. Vaccines 11(12):1862. https:\/\/doi.org\/10.3390\/vaccines11121862","journal-title":"Vaccines"},{"key":"6382_CR11","unstructured":"Mondiale de la Sant\u00e9 O (2017) World Health O. Weekly epidemiological record, 92(25):345\u2013356. Weekly Epidemiological Record\u2009=\u2009Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire 92:345\u2013356"},{"issue":"1","key":"6382_CR12","doi-asserted-by":"publisher","first-page":"18155","DOI":"10.1038\/s41598-020-75338-5","volume":"10","author":"N Miao","year":"2020","unstructured":"Miao N, Zheng H, Sun X, Zhang G, Wang F (2020) Protective effect of vaccinating infants with a 5 \u00b5g recombinant yeast-derived hepatitis B vaccine and the need for a booster dose in China. Sci Rep 10(1):18155. https:\/\/doi.org\/10.1038\/s41598-020-75338-5","journal-title":"Sci Rep"},{"issue":"4","key":"6382_CR13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/hep.32474","volume":"76","author":"MG Bruce","year":"2022","unstructured":"Bruce MG, Bruden D, Hurlburt D et al (2022) Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose. Hepatology 76(4):1180\u20131189. https:\/\/doi.org\/10.1002\/hep.32474","journal-title":"Hepatology"},{"issue":"5","key":"6382_CR14","doi-asserted-by":"publisher","first-page":"e97474","DOI":"10.1371\/journal.pone.0097474","volume":"19","author":"Z Ji","year":"2014","unstructured":"Ji Z, Wang T, Shao Z et al (2014) A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS ONE 19(5):e97474. https:\/\/doi.org\/10.1371\/journal.pone.0097474","journal-title":"PLoS ONE"},{"issue":"7","key":"6382_CR15","doi-asserted-by":"publisher","first-page":"2153535","DOI":"10.1080\/21645515.2022.2153535","volume":"18","author":"L-F Huang","year":"2022","unstructured":"Huang L-F, Lin Z-Q, Yang X-H et al (2022) Association of vaccine policy with virus infection and awareness of hepatitis B in Fujian, China. Hum Vaccines Immunother 18(7):2153535. https:\/\/doi.org\/10.1080\/21645515.2022.2153535","journal-title":"Hum Vaccines Immunother"},{"issue":"12","key":"6382_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/liv.13437","volume":"37","author":"HS Hsu ShuHua","year":"2017","unstructured":"Hsu ShuHua HS, Chih AnHsuan CA, Lee YiChin LY, Huang KuoChin HK, Jan ChyiFeng JC (2017) Higher disappearance rate of anti-HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine. Liver Int 37(12):1780\u20131787. https:\/\/doi.org\/10.1111\/liv.13437","journal-title":"Liver Int"},{"issue":"2","key":"6382_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/vaccines11020348","volume":"11","author":"T-W Cheng","year":"2023","unstructured":"Cheng T-W, Yang J-F, Chen Y-Y et al (2023) Epidemiology of chronic hepatitis B infection in the cohort of college students with vaccination in Taiwan. Vaccines 11(2):348. https:\/\/doi.org\/10.3390\/vaccines11020348","journal-title":"Vaccines"},{"issue":"4","key":"6382_CR18","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.jve.2022.100309","volume":"8","author":"K Komada","year":"2022","unstructured":"Komada K, Ichimura Y, Shimada M et al (2022) Impact of hepatitis B vaccination programs in Vietnam evaluated by estimating HBsAg prevalence. J Virus Erad 8(4):100309. https:\/\/doi.org\/10.1016\/j.jve.2022.100309","journal-title":"J Virus Erad"},{"issue":"6","key":"6382_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.bjid.2019.10.001","volume":"23","author":"M Moghadami","year":"2019","unstructured":"Moghadami M, Dadashpour N, Mokhtari AM, Ebrahimi M, Mirahmadizadeh A (2019) The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study. Braz J Infect Dis 23(6):419\u2013426. https:\/\/doi.org\/10.1016\/j.bjid.2019.10.001","journal-title":"Braz J Infect Dis"},{"key":"6382_CR20","doi-asserted-by":"publisher","first-page":"1809223","DOI":"10.1080\/19932820.2020.1809223","volume":"15","author":"W Dhouib","year":"2020","unstructured":"Dhouib W, Kacem M, Bennasrallah C et al (2020) Hepatitis B birth vaccination, cohort study, Tunisia 2000\u20132017. Libyan J Med 15:1809223. https:\/\/doi.org\/10.1080\/19932820.2020.1809223","journal-title":"Libyan J Med"},{"issue":"16","key":"6382_CR21","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1017\/S0950268816001849","volume":"144","author":"H Chaouch","year":"2016","unstructured":"Chaouch H, Hachfi W, Fodha I et al (2016) Impact and long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B vaccination in Tunisia. Epidemiol Infect 144(16):3365\u20133375. https:\/\/doi.org\/10.1017\/S0950268816001849","journal-title":"Epidemiol Infect"},{"issue":"39","key":"6382_CR22","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1016\/j.vaccine.2018.08.038","volume":"36","author":"MB Hadj","year":"2018","unstructured":"Hadj MB, Bouguerra H, Saffar F et al (2018) Observational study of vaccine effectiveness 20 years after the introduction of universal hepatitis B vaccination in Tunisia. Vaccine 36(39):5858\u20135864. https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.038","journal-title":"Vaccine"},{"issue":"7","key":"6382_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-7","volume":"14","author":"TJ Peto","year":"2014","unstructured":"Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ (2014) Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986\u201390) and in the nationwide immunisation program. BMC Infect Dis 14(7):1\u20138. https:\/\/doi.org\/10.1186\/1471-2334-14-7","journal-title":"BMC Infect Dis"},{"issue":"5","key":"6382_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/infdis\/jiab562","volume":"226","author":"AJ Stockdale","year":"2022","unstructured":"Stockdale AJ, Meiring JE, Shawa IT et al (2022) Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre. Malawi J Infect Dis 226(5):871\u2013880. https:\/\/doi.org\/10.1093\/infdis\/jiab562","journal-title":"Malawi J Infect Dis"},{"issue":"6","key":"6382_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2174\/1566524021666210928152015","volume":"22","author":"TZ Mehrizi","year":"2022","unstructured":"Mehrizi TZ (2022) An Overview of the latest applications of platelet-derived microparticles and nanoparticles in medical technology 2010\u20132020. Curr Mol Med 22(6):524\u2013539. https:\/\/doi.org\/10.2174\/1566524021666210928152015","journal-title":"Curr Mol Med"},{"issue":"5","key":"6382_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2174\/1389201023666220727141624","volume":"24","author":"TZ Mehrizi","year":"2023","unstructured":"Mehrizi TZ, Ardestani MS (2023) Therapeutic Application of Nanoparticles in Hepatitis Diseases: A Narrative Review (2011\u20132021). Curr Pharm Biotechnol 24(5):611\u2013632. https:\/\/doi.org\/10.2174\/1389201023666220727141624","journal-title":"Curr Pharm Biotechnol"},{"key":"6382_CR27","doi-asserted-by":"publisher","unstructured":"Mehrizi TZ, Vodjgani M, Keyvani H, Falak R, Javanmard A, Eshrati B et al (2024) The latest findings of gamma irradiation of blood products to prevent transfusion-associated graft-versus-host disease (TA-GVHD) in cancer patients: a systematic review. Iran J Nuclear Med 32(2). https:\/\/doi.org\/10.22034\/irjnm.2024.129494.1593","DOI":"10.22034\/irjnm.2024.129494.1593"},{"key":"6382_CR28","doi-asserted-by":"publisher","first-page":"102759","DOI":"10.1016\/j.canep.2025.102759","volume":"95","author":"TZ Mehrizi","year":"2025","unstructured":"Mehrizi TZ, Ataei-Pirkooh A, Eshrati B, Shahmabadi HE (2025) Investigating factors affecting the effectiveness of Gardasil 4, Cervarix, and Gardasil 9 vaccines considering the WHO regions in females: A systematic review. Cancer Epidemiol 95:102759. https:\/\/doi.org\/10.1016\/j.canep.2025.102759","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"6382_CR29","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00289-022-04147-9","volume":"80","author":"T Zadeh Mehrizi","year":"2023","unstructured":"Zadeh Mehrizi T (2023) Assessment of the effect of polymeric nanoparticles on storage and stability of blood products (red blood cells, plasma, and platelet). Polym Bull 80(3):2263\u20132298. https:\/\/doi.org\/10.1007\/s00289-022-04147-9","journal-title":"Polym Bull"},{"issue":"14","key":"6382_CR30","doi-asserted-by":"publisher","first-page":"2130013","DOI":"10.1142\/S1793292021300139","volume":"16","author":"TZ Mehrizi","year":"2021","unstructured":"Mehrizi TZ (2021) Impact of metallic, quantum dots and carbon-based nanoparticles on quality and storage of albumin products for clinical use. NANO 16(14):2130013. https:\/\/doi.org\/10.1142\/S1793292021300139","journal-title":"NANO"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-025-06382-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T14:06:30Z","timestamp":1757685990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-025-06382-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6382"],"URL":"https:\/\/doi.org\/10.1007\/s00705-025-06382-7","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"193"}}